CRISPR/Cas9技术(递送)在支气管上皮细胞中的应用和进展  

Application and progress of CRISPR/Cas9 strategies(delivery)in bron⁃chial epithelial cells

作　　者：张莹莹[1] 王楚雯 钱国清 ZHANG Yingying;WANG Chuwen;QIAN Guoqing(Health Science Center,Ningbo University,Ningbo 315211,China;The First Affiliated Hospital of Ningbo University,Ningbo 315211,China)

机构地区：[1]宁波大学医学部,浙江宁波315211 [2]宁波大学附属第一医院,浙江宁波315211

出　　处：《中国病理生理杂志》2025年第1期173-180,共8页Chinese Journal of Pathophysiology

基　　金：浙江省基础公益研究计划自然科学基金探索项目(No.LY23H190003);宁波市青年科技创新领军人才项目(No.2023QL055);浙江省卫生高层次人才培养基金(浙卫发[2021]-40号)。

摘　　要：规律成簇间隔短回文重复序列(CRISPR)/CRISPR相关蛋白9(Cas9)技术操作简易、高效,适用性强,在探究呼吸道潜在机制中具有独特优势。支气管上皮细胞是肺部防御的物理屏障,其损伤或功能缺失是慢性气道疾病的发病基础。近年来,慢性气道疾病发病率升高,但治疗进展相对缓慢,亟需找到治疗的突破口。CRISPR/Cas9系统可以进行精准基因编辑,为慢性气道疾病提供新策略。本文从CRISPR/Cas9的多种递送方式和作用机制出发,对其在原代、永生化支气管上皮细胞和动物体内的应用与进展进行概述,探讨了其发展前景和面临的挑战,以期为未来应用该技术进行气道疾病治疗提供参考。Clustered regularly interspaced short palindromic repeats(CRISPR)/CRISPR-associated protein 9(Cas9)technology is easy to operate,efficient,and applicable,and has unique advantages in probing the underlying mechanisms of the airways.Bronchial epithelial cells form a physical barrier of lung defense,and their damage or dysfunction involves in the pathogenesis of chronic airway diseases.In recent years,the incidence of chronic airway diseases has increased,but the progress of treatment has been relatively slow,and there is an urgent need to find a therapeutic breakthrough.The CRISPR/Cas9 system enables precise gene editing and provides a new strategy for chronic airway diseases.In this review,we provide an overview of the application and progress of CRISPR/Cas9 in primary or immortalized bronchial epithelial cells and in vivo animal models in terms of its delivery mode and mechanism,and discuss the development prospects and challenges of CRISPR/Cas9,to provide potential future role of this strategy for airway disease treatment.

关 键 词：CRISPR/Cas9系统 支气管上皮细胞 基因编辑 

分 类 号：R562.2[医药卫生—呼吸系统] R363.2[医药卫生—内科学] Q78[医药卫生—临床医学]